Non-drug treatment for hypertension found effective in hard-to-control refractory hypertensives

Image available through contact

Fort Lee, NJ -- June 30, 2003 Hard-to-control refractory hypertensives witnessed a significant blood pressure reduction when using a new non-drug treatment device, Resperate®, according to a study published in this month's American Journal of Hypertension.

The 8-week study, performed at the WHO Collaborative Center for Prevention of CVD, the Barzilai Medical Center Ashkelon, Israel, demonstrated that 15-minutes daily self treatment with the Resperate device significantly reduced the blood pressure of patients who were not achieving goal blood pressure despite taking 3 or more antihypertensive drugs at maximum dosage.

The results of the American Journal of Hypertension study are consistent with outcomes reported in six previous peer-reviewed, published studies examining the effects of the device in the general uncontrolled hypertensive patient population and a recent mechanism-of-action review published in the American Heart Association's textbook, Hypertension Primer in May, 2003.

"These are evidence of the effectiveness of Resperate as an adjunctive treatment for hypertension" said Dr. Reuven Viskoper, the principal investigator and the past president of the Israeli Society of Hypertension. "The fact that this non-drug treatment delivered the same significant blood pressure reductions even in refractory hypertensives is clinically meaningful as it provides us with a much needed effective, and side-effect-free treatment option for this patient population".

Reprints of the full text article, other peer reviewed articles and additional information about Resperate are available on request from Tom Kirwan at 201-720-7750, ext. 7136 or see http://www.resperate.com/press.

About InterCure Ltd. & Resperate® InterCure (www.intercure.com) is a medical device company pioneering the application of respiratory-pacing technology for the treatment of hypertension and heart failure. Following six successful clinical trials, Resperate http://www1.resperate.com/, InterCure's first product, became the only FDA-cleared, non-drug medical device indicated for the adjunctive treatment of hypertension. Resperate can be safely added to lifestyle modifications and/or pharmacological therapy. Resperate's blood pressure reductions are in addition to other treatments.